We look forward to sharing full results at an upcoming conference in September and based on these positive results we plan to submit a supplemental NDA for patisiran with the US Food and Drug Administration in late 2022 APOLLOB is a Phase 3 randomized doubleblind placebocontrolled multicenter global study designed and powered to evaluate the eects of patisiran on functional capacity and quality of life in patients with ATTR amyloidosis with cardiomyopathy